Back to results
US 2026/0207663 A2Published application
Cancer-killing cells
AssigneeLIfT BioSciences Ltd
InventorsAlex Blyth, Nico Bruyniks
Life of this patent
Estimating the term…
Abstract
The present invention relates to an in vitro culture of haematopoietic cells, wherein said haematopoietic cells differentiate to form granulocytes characterised by the ability to kill cancer cells. The invention also relates to said granulocytes, methods for identifying said haematopoietic cells and granulocytes, compositions and kits comprising the same, as well as uses of the same for treating cancer.
Claims20
-46. (canceled)
A pharmaceutical composition comprising:
- a. granulocyte precursor cells;
- and
- b. a granulocyte-macrophage colony-stimulating factor (GM-CSF), a granulocyte colony-stimulating factor (G-CSF), a growth hormone;
- serotonin, vitamin C, vitamin D, glutamine (Gln), arachidonic acid, AGE-albumin, an interleukin, TNF-alpha, Flt-3 ligand, thrombopoietin, foetal bovine serum (FBS), or combinations thereof.
1 more element
-57. (canceled)
Dependencies are inferred from the claim text.